Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72632 record(s)

Req # A-2019-001598

Adverse Reaction Report (AER) for NINLARO. Report number: E2B_02747790.

Organization: Health Canada

13 page(s)
March 2020

Req # A-2019-001602

Adverse Reaction Report (AER) for PANTOPRAZOLE. Report numbers: 000728933, 000729469, E2B_02721101, E2B_02726898, E2B_02727599, E2B_02733268, E2B_02738003, E2B_02742861, E2B_02743130, E2B_02745655, E2B_02747521, E2B_02747529, E2B_02751738,…

Organization: Health Canada

614 page(s)
March 2020

Req # A-2019-001612

Adverse Reaction Report (AER) for CEFIXIME. Report numbers: E2B_02555912, E2B_02432931.

Organization: Health Canada

24 page(s)
March 2020

Req # A-2019-001616

Adverse Reaction Report (AER) for CODEINE SULFATE. Report number: E2B_02200066.

Organization: Health Canada

14 page(s)
March 2020

Req # A-2019-001617

Adverse Reaction Report (AER) for leflunomide. Report number: E2B_02456998.

Organization: Health Canada

7 page(s)
March 2020

Req # A-2019-001619

Adverse Reaction Report (AER) for Cipralex® (escitalopram). Report numbers: E2B_02535962, E2B_02543869, 000726867, 000726987, 000727052, E2B_02585107 and E2B_02610804 AER for Celexa® (citalopram). Report numbers: 000724951, E2B_02528143,…

Organization: Health Canada

336 page(s)
March 2020

Req # A-2019-001732

Adverse Reaction Report (AER) for DEXILANT. Report numbers: E2B_02792258, E2B_02799100.

Organization: Health Canada

50 page(s)
March 2020

Req # A-2019-001647

Adverse Reaction Report (AER) for HYDROCODONE TARTRATE, PHENYLEPHRINE HYDROCHLORIDE. Report number: E2B_02144626.

Organization: Health Canada

10 page(s)
March 2020

Req # A-2019-001648

Adverse Reaction Report (AER) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02228615, E2B_02386796, E2B_02092633.

Organization: Health Canada

221 page(s)
March 2020

Req # A-2019-001657

Adverse Reaction Report (AER) for SODIUM AUROTHIOMALATE. Report numbers: E2B_02112424, E2B_02120344, E2B_02123701, E2B_02230814, E2B_02074075, E2B_02098052, E2B_02104850, E2B_01804139, E2B_02273808, E2B_02266431, E2B_02192705, E2B_02355882.

Organization: Health Canada

295 page(s)
March 2020
Date modified: